Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Pelthos Therapeutics Inc.AMEX: PTHS
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns positive
Q1 FY2026 total equity was $35.1M, compared with -$4.2M a year earlier.
Context
- Total equity amounted to 24.1% of total assets at the end of Q1 FY2026, down 436.3 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +936.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 38.88M USD
- Year-over-year change
- +1532.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.88M | +1532.6% |
| FY2024 | 2024-12-31 | (2.71M) | +57.9% |
| FY2023 | 2023-12-31 | (6.44M) | -73.9% |
| FY2022 | 2022-12-31 | (3.71M) | — |
Total Equity vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 total equity of $35.1M is the 2nd highest of the 4 companies compared; the peer median is $18.86M.
- Its year-over-year change of +936.6% is the 2nd highest of 4, against a peer median of +691.9%.
- Total equity amounts to 24.1% of total assets for PTHS, versus a peer median of 83.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $1.93B | +8102.8% | +224.1% | 83.2% | |
| Mar 2026 | $35.1M | +936.6% | — | 24.1% | |
| Mar 2026 | $18.86M | +218.1% | -13.5% | 61.1% | |
| Mar 2026 | $9.18M | +691.9% | +28.5% | 84.5% | |
| Peer median (excluding PTHS) | $18.86M | +691.9% | +28.5% | 83.2% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.